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Introduction. Thoracic aortic aneurysms (TAA) are the most common condition of the thoracic aorta requiring surgical
treatment. Despite significant improvement in anesthetic, surgical techniques and postoperative care, the mortality and
morbidity rate in TAA-repair remains high. The aim of this study was to assess the morbidity and mortality rate after
endovascular stent-graft treatment of atherosclerotic (non-dissecting) TAAs.
Methods. Thirty-one patients, ASA-classification III–IV, with symptomatic or expanding atherosclerotic TAAs underwent
endovascular stent-graft repair between May 1997 and August 2003. Procedures were performed on an emergency basis in
13 patients and elective in 18 patients. Patients were assessed postoperatively by routine CT-scan within 48 h. Further
follow up investigations were performed after 3, 6, 12 months and annually thereafter.
Results. Stent-graft placement was successful in all but one patient in whom the stent-graft procedure had to be postponed
due severe hemodynamic instability. Perioperative mortality rate was 19% including three haemorrhages, two cardiac events
and one respiratory failure (6/31). Technical success rate was 55% (17/31). Completion CT scans performed in 30 patients
within 2 days of stent-graft procedure showed type I leaks in seven patients (23%), type II leaks in four patients (13%) and
type III leaks in two patients (6%). Further complications included one stroke, one paralysis, one spinalis anterior syndrome
and five relevant access related complications. New onset endoleaks, all type I, were observed in seven patients (23%)
occurring after 3, 4, 7, 8, 17, 25 and 26 months. Mean follow-up was 15 months (range 2–69 months).
Conclusion. Thoracic aortic atherosclerotic aneurysm stent-grafting is feasible but not without significant morbidity and
mortality.
Key Words: Morbidity; Mortality; Endovascular repair; Atherosclerotic TAA.
Introduction
Thoracic aortic aneurysms (TAAs) are the most
common condition of the thoracic aorta requiring
surgical treatment, to avoid natural complications
such as rupture or dissection. Traditional repair of
TAA is performed by segmental resection and replace-
ment with different types of grafts.1 Despite significant
improvement in anesthesia, surgical techniques, and
postoperative care, the mortality and morbidity rate of
TAA-repair remains high. Emergency surgery is
frequently complicated by respiratory failure (51%),2
renal failure (17%),3 paraplegia (7–24%)2,3 or death
(13–50%).2,3 In addition, severe complications like
haemorrhage, stroke, cardiac events, sepsis, or bowel
ischemia may occur. In patients with TAA, open
surgery can be too hazardous, due to the high
frequency of coexisting serious comorbid medical
conditions such as coronary artery disease, hyperten-
sion, or chronic pulmonary disease, heightening the
risk for perioperative complications. Endovascular
stent-graft repair may provide an alternative treatment
option in these patients.4,5 In the absence of long-term
follow-up studies, endovascular repair of TAAs
represents a technical advance, is minimally invasive,
and appears to be a relatively safe alternative to
traditional open repair especially in high risk patients.
The aim of this study was to summarize our 6-year
experience in endovascular stent-graft treatment in a
consecutive series of patients presenting with non-
dissecting TAAs due to atherosclerosis and to assess
the morbidity, the mortality rate and midterm results.
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Methods
Patient population and data collection
FromMay 1997 to August 2003, 63 patients underwent
a thoracic endovascular stent-graft procedure at our
institution. Thirty-two patients were treated for trau-
matic rupture (12) or type B dissection (20) of the
thoracic aorta and were excluded from this study.
Therefore, 31 patients with symptomatic or progress-
ive atherosclerotic descending TAAs in whom endo-
vascular stent-graft repair was performed were
reviewed for this study. Thirteen patients were treated
for symptomatic TAAs of the descending thoracic
aorta, all on an emergency basis within 24 h after
admission. Our institution is the only hospital within
300 miles offering endovascular repair for thoracic
aortic pathologies, thus attracting a high percentage of
emergency cases. Progressive atherosclerotic descend-
ing TAAs were treated after a routine preoperative
examination including spirometry and cardiac stress
test, or coronary angiography.
Aneurysms were considered symptomatic when
the patient presented with one or more of the
following signs: severe back pain ðn ¼ 7Þ; hemody-
namic instability ðn ¼ 5Þ; hemoptysis ðn ¼ 2Þ or signs
of a covered rupture, such as mediastinal hematoma
ðn ¼ 1Þ; hemothorax ðn ¼ 6Þ; or hemorrhage into the
thrombus of the aneurysm ðn ¼ 6Þ: Progressive TAA
was defined by rapid growth in diameter of more than
0.5 cm within 6 months. Written informed consent for
endovascular treatment of the TAAwas obtained from
all patients.
Stent-graft devices
Three types of stent-grafts were used in this series:
Excluder (W.L. Gore and Associates, Inc., Flagstaff,
AZ), a modular system manufactured with an
expanded polytetrafluoroethylene prosthesis sup-
ported by a self-expanding nitinol stent exoskeleton;
Vanguard (Boston Scientific, Natick, MA), a modular
system consisting of a polyester (Dacron) graft fabric
and self-expanding nitinol endoskeleton; and Talent
(Medtronic AVE, Sunrise, FL), a self-expanding endo-
graft consisting of a polyester (Dacron) graft fabric and
self-expanding nitinol exoskeleton with bare springs
at the proximal and distal site of the covered portion.
Pre-operative imaging studies
CT angiography of the entire aorta was performed
preoperatively in all patients to determine the ana-
tomical feasibility for the stent-graft procedure, aneur-
ysm size, location, extension, and relationship
between the aneurysm and significant aortic branches
such as the left subclavian artery and the celiac trunk.
Dimensions of stent-grafts used were determined on
the basis of contrast-enhanced spiral CT images
(HiSpeed Advantage; General Electric Medical Sys-
tems, Milwaukee, WI) and angiographic images.
Exclusion criteria
General medical exclusion criteria for an endovascular
stent-graft procedure included newly diagnosed can-
cer, previous stroke with major disabling deficit,
allergy to stainless steel or polyester, and medically
intractable hypertension. Endoluminal anatomical
exclusion criteria were proximal and distal neck length
of ,15 mm, aortic landing zone diameter of .45 or
,18 mm in diameter, angulations more than 608
relative to the long axis of the aneurysm, circumfer-
ential thrombus/atheroma within the landing zone,
and iliac artery diameter ,7 mm.
Technical success rate was defined as successful
deployment of the endoluminal graft without persist-
ent perigraft endoleak (.48 h) according to the
classification standards recommended in the Society
for Vascular Surgery and International Society for
Cardiovascular Surgery.6
Endovascular stent-graft procedure
All procedures were performed under general
anesthesia by a team of vascular surgeons and
interventional radiologists in the endovascular suite
with fluoroscopic and angiographic equipment. All
patients received prophylactic preoperative anti-
biotics. After surgical exposure of the femoral artery,
a calibrated angiographic pigtail catheter (Cook, Inc.,
Bloomington, IN) was placed in the ascending aorta,
followed by an angiography to confirm the beginning
of the aneurysm, to mark the left subclavian artery,
and to determine the final landing zone. A super stiff
guide wire (Back up Meier, Boston Scientific) was
inserted and passed above the aneurysm. Adminis-
tration of 5000 IU Heparin was followed by insertion
of the stent-graft system. Just before the device was
released, systolic arterial blood pressure was lowered
by nitro-prusside to 70 mmHg. An inflatable balloon
was used to model the stent-graft to the aortic wall. If
two or more stent-grafts were used for complete
aneurysm exclusion, an overlapping zone of at least
3 cm was chosen within the grafts. The routine graft-
oversizing rate was 15%; the minimum is 10% and
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maximum 25% relative to the aorta at the fixation sites.
In patients with a short proximal landing zone the
origin of the left subclavian artery was crossed with
the uncovered or covered portion of the stent-graft to
extend the landing zone. A subclavian-to-carotid
bypass procedure was performed in one patient
prior to the stent-graft procedure to avoid an over-
stenting of the left internal mammary artery, which
had been used for myocardial revascularization 2
years earlier. Completion angiography was performed
to ensure complete sealing and adequate device
placement and to assess the adequacy of the repair.
All patients received approximately 70–120 ml of
intravenous non-ionic contrast medium during the
stent-graft procedure. Techniques to prevent paraple-
gia (i.e., spinal fluid drainage) were not used. A
complete CT scan was performed within 2 days post-
procedure in all patients to confirm complete sealing
of the aneurysm and identify any endoleaks.
Follow-up investigations
Median follow-up time was 15.1 months (range 4–69
months). Clinical examinations and contrast-enhanced
spiral CTwere performed after 3, 6, and 12months and
annually thereafter, or more frequently if necessary to
investigate suspected complications. Intra-arterial
digital subtraction angiography (DSA) was done in
cases of suspected complications. The presence and
source of endoleaks are classified at all time intervals
according to the standard classification.7 If type I or
type III endoleaks were observed on CT scans,
treatment was always recommended. Migration of
stent-grafts was evaluated by comparing three-dimen-
sional volume rendering reconstructions of the grafts
in different planes. Device migration was treated when
it was associated with type I endoleak.
Statistical evaluation
Statistical analysis was performed with the Statistical
Package for Social Sciences (SPSS) for Windows 10.1.3,
with Kaplan–Meier survival analyses.
Results
Thirty-one patients, 25 males (81%) and six females
(19%), mean age 73 years (range 65–81) with sympto-
matic (13 (42%)) or progressive non-dissecting athero-
sclerotic TAAs (18 (58%)) were treated by
endovascular stent-graft repair. Demographics and
comorbid medical conditions are listed in Table 1. The
aortic pathology was located in the proximal descend-
ing aorta in 20 patients (65%), in the mid-descending
aorta in four patients (13%), and in the distal
descending aorta in six patients (19%). One patient
had two aneurysms located at the proximal and distal
descending aorta (3%). The stented segment of the
descending thoracic aorta was between the origin of
the left subclavian artery and the proximal descending
aorta in 11 patients, between the left subclavian artery
and the mid-descending aorta in six patients, between
the left subclavian artery to the distal descending aorta
in five patients, between the mid-descending aorta
and distal descending aorta in two patients, and
confined to the distal descending aorta in seven
patients. The median aneurysm diameter was
65 mm ^ 22 (range 25–110) and included fusiform
ðn ¼ 27Þ and saccular ðn ¼ 4Þ aneurysms.
The devices were inserted via a femoral route in 25
patients (81%). A retroperitoneal approach via the
common iliac artery was performed in four patients
(13%). Simultaneous repair of an infrarenal aortic
aneurysm .6 cm and TAA was performed in two
patients (6%), due to an increasing risk of rupture of
both aneurysms, using the polyester tube graft for
stent-graft insertion during an elective procedure. In
both patients the TAA was successfully excluded.
However, both patients died postoperatively due to
myocardial infarction after 1 and 11 days, despite
unremarkable preoperative coronary angiography.
Access-related complications
Severe access-related complications were observed in
three patients. In two patients introduction of the
stent-graft system caused a perforation of the common
iliac artery requiring an emergency retroperitoneal
approach to create an iliac-femoral bypass. The post-
operative course was uneventful. In one patient a
femoral artery reconstruction had to be performed.
Stent-grafts
In total, 59 endovascular stent-grafts (44 Talent, 2
Vanguard, and 13 Gore) were placed to complete
aneurysm coverage in the 31 patients. A single stent-
graft was used in 12 patients (39%), two in 12 (39%),
three in 6 (19%) and five stent-grafts were placed in
one patient (3%). The left subclavian artery was fully
covered in eight patients, by bare springs in 11
patients, and uncovered in 12 patients. None of the
patients developed an upper arm ischemia. No
revascularisation procedure was necessary after the
initial endovascular stent-graft procedure. Primary
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stent-graft placement was successful in all patients.
However, in one patient in whom a retroperitoneal
iliac-femoral bypass for adequate access was per-
formed first, the stent-graft placement had to be
postponed due to serious instability during the retro-
peritoneal access preparation. Six months later the
thoracic stent-graft was placed successfully via the
iliac-femoral bypass. Technical success rate was 55%
(17/31).
Mortality
Overall 30-day operative mortality was 19% (6/31),
16% in those undergoing elective treatment (3/18) and
23% in those undergoing emergency treatment (3/13).
Three peri-operative deaths were directly aneurysm
related. Aorto-bronchial fistula due to increasing
proximal descending aortic aneurysms (70 and
110 mm in diameter) and failed aneurysm exclusion
with proximal type I and type III endoleak after
endovascular repair resulted in compression and
finally erosion of the bronchial system in two patients.
These findings were confirmed by autopsy. Failed
aneurysm exclusion resulted in aneurysm rupture into
the pleural cavity in the third patient. Three other
deaths were due to myocardial infarction (2) or
respiratory failure (1). The cumulative survival rate
was 68.5, 61.1, and 47.4 after 6, 12 and 24 months,
respectively (Fig. 1). These six deaths accounted for
19% of a total of 13 deaths as listed in Table 2.
Morbidity
The results of 48 h CT scans to detect endoleak
(performed in 30 patients) are listed in Table 3. Early
type 1 endoleaks were observed in four patients (19%),
type III endoleaks in two patients and late type I
endoleaks in five patients (24%) after Talent stent-graft
deployment. Early type I leak occurred in three
patients (33%), and late type I endoleaks occurred in
one patient (11%) after Gore stent-graft deployment.
Type I endoleaks was treated by additional stent-graft
procedures on postoperative days 2 and 18. Conver-
sion to open surgery on postoperative day 17was done
in one patient due to anatomical unsuitability for an
additional stent-graft procedure. In two patients no
further endovascular therapy was possible due to
anatomical limitations. In both patients the ostium of
the left carotid artery was covered with bare springs:
however, type I leak sealing could not be achieved.
Open surgery was impossible due to serious comor-
bidity. Both patients died on postoperative day 8 of
haemorrhage from aortobronchial fistula (1) and
aneurysm rupture (1), respectively. Further therapy
was declined by one patient; another patient devel-
oped a stroke on the first postoperative day and
declined further therapy, after partial stroke recovery.
Both patients survived 12 and 30 months after stent-
grafting but follow-up investigations have been
declined. Completion type III leaks were observed in
Fig. 1. Two-year cumulative survival (Kaplan–Meier). Time,
months after intervention; at risk, number of patients
exposed to risk; SE, standard error of cumulative survival.
Table 1. Demographic details
n ¼ 31 (%)
Male/female 25/6 81/19
Mean age 72 (65–81)
ASA-classification III/IV 17/14 55/45
Symptomatic/asymptomactic TAAs 13/18 42/58




Coronary artery disease 28 90
Renal retention 15 48
COPD 14 45
Table 2. Mortality
Mortality Emergency n ¼ 13
(42%)
Elective n ¼ 18
(58%)
Early TAA related mortality 2 1
Early TAA unrelated mortality 1 2
Late TAA related mortality 1
Late TAA unrelated mortality 1 5
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two patients. One patient died on the first post-
operative day due to aorto-bronchial fistula, but the
second patient was treated successfully by an
additional stent-graft procedure on postoperative
day 1. Two out of four type II leaks (13%) sealed
spontaneously after 3 months, and two with stable
aneurysm diameter are under observation.
New onset endoleaks, at later follow up, were
observed in seven patients (23%) and are listed in
Table 3. Type I leaks were treated successfully by
additional stent-graft procedures in four patients. Two
patients declined further therapy, and in one patient
the distal type I leak could not be sealed due to close
proximity of the celiac trunk. One patient had
additional covered ruptures due to disease pro-
gression and developed haemoptysis after 5.4 and
6.4 months postoperatively. In this specific patient,
three additional stent-graft procedures were per-
formed; the fourth stent-graft procedure ended with
a persisting type I endoleak without further possibility
of additional minimal invasive procedures. This
patient finally died 7 months after his first stent-graft
procedure due to aortic rupture located at the
juxtaposition of the proximal stent-graft area.
Aneurysm progression was observed at the prox-
imal or distal end of the stent-graft in two patients
(6%) treated for penetrating ulcer. In one of these
patients an additional stent-graft procedure was
performed after 4 months; the patient developed a
type I endoleak after 6 months and was treated by a
third successful stent-graft procedure. The second
patient declined further therapy. One patient devel-
oped a type A dissection after 4 months post-
procedure and underwent emergency replacement of
the aortic valve and ascending aorta with an unevent-
ful postoperative course, at another hospital. The same
patient developed a type III endoleak after 26 months
and was successfully treated by an additional stent-
graft procedure. A total of eight patients (26%) had
additional stent-graft procedures due to new onset of
endoleaks or disease progression. Four patients had 2,
three patients had 3, and one patient had 4 additional
stent-graft procedures.
Two patients (6%) manifested postoperative neuro-
logical deficits due to spinal cord ischemia, delayed
onset was observed in one patient. Retrospectively,
both patients had an increased risk for developing
neurological deficits. In one patient, AAA repair had
been performed 4 years earlier. The left subclavian
artery was covered by bare springs, and vital inter-
costal arteries were covered by three thoracic stent-
grafts placed for complete TAA exclusion resulting in
complete paraplegia without recovery. The second
patient developed a bilateral leg weakness on post-
operative day 3, after placement of a single stent-graft
for proximal descending TAA exclusion. The orifice of
left subclavian artery was fully covered by the covered
portion of the stent-graft resulting in reduced blood
supply to the spinal cord through the anterior spinal
artery. Further intercostal arteries were lost due to a
coexisting 5 cm infrarenal aortic aneurysm. The
patient’s symptoms improved with physiotherapy,
giving partial recovery.
Other 30-day morbidity, excluding endoleaks, was
32% (10/31) including major and minor events listed
in Table 4.
Table 3. Endoleaks after endovascular repair of atherosclerotic descending TAA
Patients (age) Treatment TAA Deployed stent-grafts 48 h endoleaks Late endoleaks (months) Follow-up m, months
1 (74) Elective MDA T (1) II I a (26) M* 69 m
2 (77) Elective PDA T (2) I a I a (25) M* 57 m
3 (68) Acute PDA T (5) III Day 1†
4 (75) Elective PDA T (2) I a Day 8†
5 (73) Acute PDA T (3) I a Conversion day 17
6 (73) Acute DDA T (1) II 15 m
7 (70) Elective PDA T (1) I a 7 m
8 (80) Acute PDA T (2) III Day 24†
9 (80) Acute DDA G (2) I b III (3) 42 m†
10 (73) Elective PDA and DDA G (2) I a 32 m
11 (76) Acute PDA G (1) I a Day 8†
12 (70) Elective DDA G (2) II 19 m
13 (79) Acute PDA G (2) II I a (8) 16 m
14 (75) Elective MDA T (3) – I b (4) 17 m†
15 (74) Acute PDA T (1) – I b (15) 7 m†
16 (65) Acute MDA T (3) – I b (17) 20 m
TAA location: PDA, proximal descending aorta; MDA, mid-descending aorta; DDA, distal descending aorta; T, Talent; G, Gore; (used
number of deployed stent-grafts); I a, proximal type I endoleak; I b, distal type I endoleak.
*M, migration.
†Deceased.
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Discussion
Volodos et al.8 first reported the endovascular repair of
a descending TAA in 1991. Since then several centers
have documented the feasibility of stent-graft repair
for descending TAAs.9–18 Obvious advantages of the
endovascular approach are minimal invasiveness; few
ischemic events to the spinal cord, viscera, and
kidneys; and minimal blood loss. However, the
major drawbacks for this procedure within the
atherosclerotic thoracic aorta are anatomical con-
straints, such as short or wide proximal or distal
landing zones, severe neck angulation, tortuous or
stenotic access arteries and aneurysm location. Invol-
vement of the proximal descending aorta and short
proximal aortic necks indicate anatomical difficulties
for a tight circumferential proximal seal resulting in
initial type I endoleaks. The early endoleak rate in our
series was 32%, which is similar to that reported for
other studies (Table 5). All patients with early type I
endoleaks, four acute and three elective procedures,
were treated for severe disease of the proximal
descending aorta (Table 3). The occurrence of proximal
type I endoleaks in our series possibly was related to
three factors; device characteristics, patient selection
and sub-optimal device size in emergency cases. The
Gore device resulted in 33% of early type I endoleaks,
and the Talent device had 19% of early type I
endoleaks diagnosed by 48 h CT-scan. Both type of
stent-grafts were incapable of accommodating the
curved geometry of the aortic arch and thus forming a
tight seal, despite repeated balloon dilation of the
severely diseased aortic wall. It is well known that the
Gore prosthesis has a better longitudinal flexibility for
adapting to the aortic curve of the distal arch than the
Talent device, which has a semi-rigid design. How-
ever, in our study group, endoleak rate did not differ
substantially, between these two devices. However,
the Gore stent-graft has been withdrawn, leaving the
Talent prosthesis as the single commercially available
device for thoracic aortic stent-grafting. Based on our
experience, the Talent stent-graft provides acceptable
results in patients with a proximal neck equal to or
greater than 36 mm and TAA locations distal to the
aortic arch. However, the Talent stent-graft is sub-
optimal in patients with a proximal neck less than
36 mm or those with a tortuous and/or steeply angled
aortic arch. Emergency stent-grafting is more demand-
ing compared to elective endovascular repair. Stent-
grafts must be taken from the shelf for emergency
stent-grafting and not every particular size can be
accommodated. Therefore early type I or type III
endoleaks occur more frequently than in elective cases,
as is demonstrated in our study (6/13 acute: 46%,
versus 4/18 elective: 22%). Bell et al.17 reported similar
results with 46% endoleaks after urgent or emergency
thoracic endovascular procedures in 24 patients. More
flexible commercially developed stent-grafts are under
investigation and may lower the frequency of
complications.
Degenerative disease and atherosclerotic aneurysm
formation of the thoracic aorta are diffuse and
progressive in character, often involving the entire
thoracic aorta.9,19 Endovascular treatment may result
in neo-aneurysm formation or retrograde dissection at
the distal and proximal ends of the stent-graft, as seen
in our study. Changes within the proximal and distal
neck caused by disease progression have been
reported.12,18 We observed neck dilatation at the
attachment sites after 3, 4 and 17 months respectively,
reversing the primary sealing in two patients. Both
patients were treated with Talent stent-grafts. Bare
springs at the proximal and distal site of the covered
portion of the graft may support the neo-aneurysm
formation in addition to disease progression; however,
we have no evidence regarding this theory. Both
patients remain alive.
The incidence of delayed onset endoleak was 23%
(7/31), with endoleaks detected between 3 and 26
months. Talent stent-grafts were used in five cases and
Gore stent-grafts in two of these cases. Both types of
stent-grafts failed to preserve the initial successful
aneurysm exclusion. Obvious migration was observed
in two patients after 25 and 26 months, respectively,
due to progressive aortic neck dilatation. These late
complications show the necessity of mandatory life-
long follow-up.
Covered aortic rupture is another entity seemingly
ideally suited to stent-graft repair. However, the
progressive disease itself is limiting the success rate.
Ten patients with contained atherosclerotic aortic
rupture, unsuitable for open surgery due to serious
comorbidity, were treated by stent-graft repair in our
series. In one conversion to open surgery and in two
patients, not suitable for open surgery, type I endo-
leaks remained at the end of the procedure without
Table 4. 30-day morbidity excluding endoleaks
Complication Acute n ¼ 13
(42%)








Lower extremity ischemia 1 1
Groin wound infection 2
Groin haemato-seroma 3
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further treatment options. Hospital mortality within
this group was 20% (2/10), and the late mortality rate
was 30% (3/10). These results are similar to open
surgery results; however, none of these patients was a
candidate for open surgery and it is likely that they
would not have survived without treatment. Therefore
we consider that thoracic aortic endovascular repair
offers the benefit of treatment to a group of patients
who may otherwise stay untreated with worse prog-
nosis.2 The natural course of TAA following diagnosis
in untreated patients is a 2-year survival of less than
30%, with half of all deaths occurring as a result of
aneurysm rupture. Our patient survival at 2 years was
61%, almost twice as much as without treatment.
The operative mortality rate in our series was 19%,
which is similar to other study groups.17,18 However,
considering that all the procedures were performed in
high-risk patients, we believe that this early mortality
rate is acceptable. The long termmortality 42% (13/31)
was significantly influenced by the preoperative
patient status, especially by the coronary status. Five
out of 13 deaths occurred due to myocardial failure
within a time frame of 1 day to 17 months.
Stent-graft placement requires an adequate size of
arterial approach with limited tortuosity of the iliac
vessels. The 46 mm Talent device, for instance,
requires at least a 24F sheath for delivery. Taking that
into account, access-related complications are com-
mon events. White et al.19 reported a femoral artery
reconstruction rate of 27% (7/26). Similar experiences
were reported by other study groups.12,15,18 In our
series, three patients (10%) required iliac or femoral
artery repair. Further access related complications
observed were a retroperitoneal hematoma in one
patient in whom a tube graft was performed for
infrarenal aortic aneurysm exclusion. Uneventful
relaparotomy was performed on postoperative day 1.
In two patients, embolic events resulted in lower
extremity ischemia. Access-related complications
could be reduced by stricter patient selection.
Spinal cord ischemia remains a significant problem
with both endovascular and conventional repair. In
patients treated by endovascular repair the paraplegia
rates are reported to vary from 0 to 12%.5,12,13 Green-
berg et al.12 reported three out of 25 patients (12%) with
neurological deficits after endovascular TAA exclu-
sion. Mitchell et al.8 reported four patients (3.7%) with
paraplegia in a series of 108 patients and a paraplegia
rate of 11% (2/19 patients) in patients having
simultaneous surgical repair of AAA and placement
of thoracic stent-graft. None of our patients who had
simultaneous AAA and TAA repair experienced
neurological deficits. However, two patients (6%)
manifested postoperative neurological deficits due to
spinal cord ischemia. Retrospectively, both patients
had an increased risk for developing neurological
deficits. One patient had a coexisting untreated
,4.5 cm AAA and in the other patient surgical AAA
repair had been performed 4 years earlier. Therefore in
both patients intercostal arteries were already
excluded due to pre-existing disease. Additional vital
intercostal arteries were covered by one/three thoracic
stent-grafts resulting in neurological deficits. The
presence of both thoracic and infrarenal aortic aneur-
ysms make the decision of endovascular versus open
repair more difficult. The need for durable repair must
be balanced with preservation of intercostal blood
flow; in uncertain situations, it might be unavoidable
to leave high-risk patients without treatment.
In general, endovascular stent-grafting for descend-
ing TAAs offers a less invasive alternative to conven-
tional open repair in high-risk patients. Stent-grafting
of atherosclerotic TAA is feasible in selected patients,
although it is not without relevant morbidity and
mortality. The relatively high complication rate might
be partially caused by the rigidity and shortness of the
Talent stent-graft, the only constantly available device
during our study period. New thoracic stent-grafts are
being developed. Current limitations such as early and
late device failure may improve with better proximal
and distal fixation devices and more flexible stent
grafts.
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